drugset / Trial / NCT05741086

Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)

NCT05741086

RandomizedParallel-groupSingle-blindTreatment

Summary

The primary goal of the trial is to investigate whether the experimental arms (receiving the Proprotein Convertase Subtilisin-Kexin Type 9 \[PCSK9\] inhibitor Evolocumab plus statin) could cause more changes from baseline in intracranial atherosclerotic plaque and hemodynamic features during 1 year of follow-up, compared with the control arm (taking statin) in patients with recent stroke/transient ischemic attack (TIA) caused by intracranial artery stenosis.

Timeline

Start
2023-04-15
Primary completion
2024-08-31
Completion
2024-08-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Evolocumab Monoclonal antibody 140 mg
Background Atorvastatin Small molecule 20 mg
Background Atorvastatin Small molecule 40 mg